Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered serious bleeding events. Pharmaceutical companies, such as the makers of Xarelto, have a duty to make sure that their drugs are reasonably safe for use - and failure to do so might be grounds for compensation. Our lawyers are working difficult to acquire those hurt by the drug the compensation they're entitled to.Although bleeding is a frequent complication linked with anticoagulants, it has been alleged that Xarelto is a lot more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning effects. This indicates that, within the occasion of an emergency, patients may be at danger for irreversible bleeding issues, which includes life-threatening internal and gastrointestinal hemorrhaging.Should you or perhaps a loved one suffered a significant bleeding event right after taking Xarelto, you might have legal recourse. For much more details, contact us nowadays to have your case reviewed, cost-free of charge.Compensation Possibilitiesxarelto-compensation-photoThe plaintiffs in these lawsuits are in search of compensation from Bayer and Janssen for previous and future medical bills, lost wages, pain and suffering and, in instances of death, funeral expenses. Moreover, they may be in search of punitive damages, that are normally awarded to punish the defendant and deter other firms from acting similarly.Why Are Lawsuits Getting Filed?Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs within the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.The makers of the drug continue to market when was xarelto put on the market as a safe anticoagulant option.Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.Visit this page for much more data on the alleged health risks of Xarelto.Multidistrict Litigation Trial Dates SetThe attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.